COSCIENS Biopharma (CSCI) 6-K Current report (foreign)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549____________________

FORM 6-K____________________

REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2018

Commission File Number: 0-30752____________________

Aeterna Zentaris Inc.

(Translation of registrant’s name into English)____________________

315 Sigma Drive, Suite 302DSummerville, South Carolina, USA 29486

(Address of principal executive office)____________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.Form 20-F ☒      Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

This report on Form 6-K, including the exhibit hereto, shall be deemed incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File Nos. 333-224737, 333-210561, 333-200834) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

DOCUMENTS INDEX

Exhibit	Description
99.1	Material Change Report of the Registrant dated  November 6, 2018.

SIGNATURE

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 6, 2018
	AETERNA ZENTARIS INC.
	/s/ Leslie Auld
	Leslie Auld
	Chief Financial Officer